Schouwers, Sofie, Bonnet, Myriam, Verschueren, Patrick et al. · Clinical chemistry and laboratory medicine · 2014 · DOI
This study tested a new automated machine system that measures antinuclear antibodies (ANA)—proteins the immune system sometimes makes that can indicate autoimmune diseases. Researchers found that the machine's measurement of fluorescence brightness (how bright the antibody signals are) correlates with disease likelihood: brighter signals were more likely to indicate rheumatic diseases like lupus or Sjögren's syndrome. This automated brightness measurement could help doctors better interpret ANA test results.
For ME/CFS patients, improved ANA testing interpretation matters because autoimmune phenomena are being investigated in ME/CFS pathogenesis, and some ME/CFS patients have elevated or positive ANA results. Better standardized, quantitative reporting of ANA intensity could help researchers distinguish true autoimmune co-morbidities from background positivity, and may improve diagnostic clarity for patients with overlapping or uncertain immune profiles.
This study does not prove that fluorescence intensity changes cause disease symptoms or disease progression. It is a cross-sectional diagnostic accuracy study and does not establish causal mechanisms, natural history, or whether ANA intensity predicts clinical outcomes. The inclusion of CFS patients as a control group does not determine whether ANA abnormalities are relevant to ME/CFS pathogenesis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →